MDL 29951 acts as an agonist at GPR17, inhibiting maturation of primary oligodendrocytes and potentially promoting myelin repair in models of multiple sclerosis. MDL 29951 also inhibits NMDA receptors at the glycine site as well as fructose 1,6-bisphosphatase. This compound displays neuromodulatory, anticonvulsant, and antinociceptive activities. In vivo, MDL 29951 inhibits formalin-induced licking. In animal models of seizures, this compound increases thresholds for the development of chemically-induced seizures.